000			03904nam a22007217a 4500
008			131223s20132013 xxu||||| |||| 00| 0 eng d
022			_a1941-9651
040			_aOvid MEDLINE(R)
099			_a23633132
245			_aPercutaneous mitral valve repair in the initial EVEREST cohort: evidence of reverse left ventricular remodeling.
251			_aCirculation. Cardiovascular imaging. 6(4):522-30, 2013 Jul.
252			_aCirc Cardiovasc Imaging. 6(4):522-30, 2013 Jul.
253			_aCirculation. Cardiovascular imaging
260			_c2013
260			_fFY2014
266			_d2013-12-24
520			_aBACKGROUND: Percutaneous repair of mitral regurgitation (MR) permits examination of the effect of MR reduction without surgery and cardiopulmonary bypass on left ventricular (LV) dimensions and function. The goal of this analysis was to determine the extent of reverse remodeling at 12 months after successful percutaneous reduction of MR with the MitraClip device.
520			_aCLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00209339, NCT00209274.
520			_aCONCLUSIONS: Patients with pre-existing LV dysfunction demonstrate reverse remodeling and improved LV ejection fraction after percutaneous mitral valve repair.
520			_aMETHODS AND RESULTS: Of 64 patients with 3 and 4+ MR who achieved acute procedural success after treatment with the MitraClip device, 49 patients had moderate or less MR at 12-month follow-up. Their baseline and 12-month echocardiograms were compared between the group with and without LV dysfunction. In patients with persistent MR reduction and pre-existing LV dysfunction, there was a reduction in LV wall stress, reduced LV end-diastolic volume, LV end-systolic volume and increase in LV ejection fraction in contrast to those with normal baseline LV function, who showed reduction in LV end-diastolic volume, LV wall stress, no 131223 in LV end-systolic volume, and a fall in LV ejection fraction.
546			_aEnglish
650			_a*Cardiac Catheterization
650			_a*Heart Ventricles/pp [Physiopathology]
650			_a*Mitral Valve Annuloplasty
650			_a*Mitral Valve Insufficiency/th [Therapy]
650			_a*Ventricular Dysfunction, Left/pp [Physiopathology]
650			_a*Ventricular Function, Left
650			_a*Ventricular Remodeling
650			_aAged
650			_aAged, 80 and over
650			_aAnalysis of Variance
650			_aCanada
650			_aCardiac Catheterization/is [Instrumentation]
650			_aCardiac Catheters
650			_aEquipment Design
650			_aFemale
650			_aHeart Ventricles/us [Ultrasonography]
650			_aHemodynamics
650			_aHumans
650			_aMale
650			_aMiddle Aged
650			_aMitral Valve Annuloplasty/is [Instrumentation]
650			_aMitral Valve Insufficiency/pp [Physiopathology]
650			_aMitral Valve Insufficiency/us [Ultrasonography]
650			_aProspective Studies
650			_aRecovery of Function
650			_aSeverity of Illness Index
650			_aStroke Volume
650			_aTime Factors
650			_aTreatment Outcome
650			_aUnited States
650			_aVentricular Dysfunction, Left/us [Ultrasonography]
651			_aMedStar Heart & Vascular Institute
657			_aClinical Trial, Phase II
657			_aJournal Article
657			_aMulticenter Study
657			_aRandomized Controlled Trial
657			_aResearch Support, Non-U.S. Gov't
700			_aWeissman, Neil J
790			_aEVEREST Investigators, Fail PS, Feldman T, Foster E, Glower DD, Grayburn PA, Hermiller J, Herrmann HC, Kar S, Kwan D, Lim DS, Rinaldi MJ, Rogers JH, Schwartz A, Weissman NJ, Whitlow PL
856			_uhttp://dx.doi.org/10.1161/CIRCIMAGING.112.000098 _zhttp://dx.doi.org/10.1161/CIRCIMAGING.112.000098
942			_cART _dArticle
999			_c1429 _d1429